US Bancorp DE Sells 1,571 Shares of Insmed, Inc. $INSM

Key Points

• US Bancorp DE has reduced its stake in Insmed, Inc. by 13.9%, selling 1,571 shares, leaving them with 9,752 shares valued at approximately $981,000.
• Several analysts have raised their price targets for Insmed, with Jefferies increasing their target to $148.00, indicating a strong buy sentiment for the stock.
• Insmed's recent quarterly earnings report showed a revenue of $107.42 million, surpassing estimates, although it reported a loss of ($1.70) earnings per share, missing analyst projections.

US Bancorp DE lowered its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 13.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,752 shares of the biopharmaceutical company's stock after selling 1,571 shares during the quarter. US Bancorp DE's holdings in Insmed were worth $981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. M&T Bank Corp boosted its position in Insmed by 4.7% during the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after purchasing an additional 147 shares in the last quarter. ORG Partners LLC boosted its holdings in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares in the last quarter. Cullen Frost Bankers Inc. boosted its holdings in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Insmed by 6.5% in the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after acquiring an additional 228 shares in the last quarter. Finally, Hilltop National Bank acquired a new stake in Insmed in the second quarter worth about $28,000.

Analysts Set New Price Targets

Several equities research analysts have weighed in on INSM shares. Jefferies Financial Group raised their price target on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a report on Wednesday, August 13th. UBS Group raised their price target on Insmed from $140.00 to $194.00 and gave the stock a "buy" rating in a report on Tuesday. William Blair started coverage on Insmed in a report on Wednesday, August 20th. They issued an "outperform" rating for the company. Truist Financial raised their price target on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Finally, Morgan Stanley raised their price target on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and a consensus target price of $152.88.

Insider Activity at Insmed

In related news, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the completion of the transaction, the director directly owned 262,675 shares in the company, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. This represents a 19.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 211,057 shares of company stock valued at $27,438,126 in the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Insmed Stock Up 1.6%

Shares of INSM stock opened at $165.76 on Friday. The stock has a 50 day moving average of $143.38 and a 200 day moving average of $104.83. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The stock has a market cap of $35.04 billion, a P/E ratio of -29.03 and a beta of 1.03. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $166.44.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm's revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.